Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling 510,812 shares, an increase of 316.9% from the February 12th total of 122,516 shares. Currently, 32.3% of the shares of the stock are sold short. Based on an average daily volume of 21,928,279 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 21,928,279 shares, the short-interest ratio is presently 0.0 days. Currently, 32.3% of the shares of the stock are sold short.

Institutional Trading of Cardio Diagnostics

A hedge fund recently raised its stake in Cardio Diagnostics stock. DRW Securities LLC lifted its position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,463 shares of the company’s stock after acquiring an additional 22,298 shares during the period. DRW Securities LLC owned approximately 2.21% of Cardio Diagnostics worth $110,000 at the end of the most recent quarter. 8.06% of the stock is currently owned by institutional investors.

Cardio Diagnostics Stock Up 2.7%

Shares of Cardio Diagnostics stock opened at $4.99 on Wednesday. The business has a fifty day simple moving average of $2.60 and a 200 day simple moving average of $3.32. The stock has a market cap of $9.13 million, a PE ratio of -1.33 and a beta of 2.28. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $17.39.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.